Updated:
Endo Investors
Eric Edidin founded Endo Investors in 2013 to back early-stage life-sciences companies targeting chronic disease.
Endo Investors
Endo Investors launched in 2013 as a direct response to a gap in early-stage capital for companies addressing diabetes and related chronic conditions. Founder Eric Edidin brought institutional credit and private equity experience from York Capital Management, Morgan Stanley Capital Partners, and Blackstone Group. He concurrently leads Three B Holdings, a private family investment company, and chairs BH3 Management, a real estate investment firm. The firm is based in Hollywood, Florida. Endo makes direct early-stage and venture investments across the life-sciences spectrum, concentrating on diabetes technology, metabolic disease, and infectious-disease platforms. Its portfolio spans medical devices, digital health coaching, and biotechnology. Confirmed positions include Bigfoot Biomedical, which was acquired by Abbott Laboratories in September 2023; Biolinq, which develops intelligent continuous glucose monitors; and Vironexis, a developer of viral-vector-based immunotherapies for hepatitis B and virus-associated cancers. The firm also held Capillary Biomedical, sold to Tandem Diabetes Care in July 2022, and Locemia Solutions, whose needle-free glucagon rescue treatment Baqsimi was licensed to Eli Lilly and launched commercially in 2019. Investments are concentrated in North America. The firm does not publicly disclose assets under management or total capital deployed. Edidin operates with a lean, often single-decision-maker structure, drawing on his parallel roles across real estate and institutional asset management. A notable recent event: in September 2023, portfolio company Bigfoot Biomedical was acquired by Abbott Laboratories, providing a liquidity event that underscores Endo's thesis-driven exit strategy. Endo's structure blends an emotional, patient-centered mandate with the discipline of a multi-strategy investor. Edidin's concurrent oversight of Three B Holdings and BH3 Management creates a capital-formation architecture that can support life-sciences ventures from family-office and institutional pools, distinguishing the firm from venture funds that rely solely on third-party limited partners.
General information
Firm type
Private Equity
Year founded
2013
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Hollywood
Corporate office
Hollywood, FL, United States
Principals
Eric Edidin
Founder
Sector focus
Frequently asked questions
Who runs investment decisions at Endo Investors?
Eric Edidin, the founder, leads investment decisions. He draws on institutional investment experience from York Capital Management, Morgan Stanley Capital Partners, and Blackstone Group. He also oversees Three B Holdings, a private family investment company, and chairs BH3 Management, a real estate firm.
How does Endo Investors source proprietary deal flow?
The firm leverages Edidin's long-standing networks across institutional asset management and his personal proximity to the diabetes ecosystem. His daughter's diagnosis created direct connections to clinicians, researchers, and patient-advocacy groups. Edidin's former board role with JDRF of Los Angeles also provides access to early-stage innovations in diabetes care.
Is Endo Investors structured as a single family office or does it operate more like a venture firm?
Endo operates as a private equity asset manager, though it sits within a broader family-investment architecture. Edidin concurrently serves as president of Three B Holdings, a private family investment company, and executive chairman of BH3 Management. The firm does not disclose whether it manages external limited-partner capital alongside Edidin's own.
What investment stages does Endo Investors typically target?
Endo focuses on early-stage, venture, and growth-stage life-sciences companies, with occasional restructuring situations. The firm has backed preclinical biotechnology companies such as Illuminare Biotechnologies and clinical-stage firms like ILiAD Biotechnologies, alongside later-stage digital health platforms like Cecelia Health.
Which sectors does Endo Investors explicitly avoid?
Endo does not publicly publish an exclusion list, but its entire known portfolio concentrates on life sciences, specifically diabetes technology, metabolic disease, infectious disease, and chronic-condition management. No disclosed investments sit outside healthcare.
How is Endo Investors related to Three B Holdings and BH3 Management?
Eric Edidin is the connective figure. He founded Endo Investors in 2013, serves as president of Three B Holdings, and acts as executive chairman of BH3 Management. The firms share a principal but maintain separate mandates: direct life-sciences venture, family-office investing, and real estate respectively.
Does Endo Investors maintain philanthropic structures, and how are they separated?
The firm itself lists no philanthropic arm, but Edidin has a history of board service with JDRF of Los Angeles, the Jewish Communal Fund of NY, and the Jewish Federation of Los Angeles. He currently serves on the board of ELNET US and chairs ELNET–Central and Eastern Europe. These roles are separate from Endo's investment activities.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: